Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 5 PART I, 1998, Pages 1436-1440

  Grosset, Jacques ^a   Lounis, Nacer ^b   Truffot Pernot, Chantal ^b   O'Brien, Richard J ^b   Raviglione, Mario C ^b   Ji, Baohong ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0031747939     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.5.9709072     Document Type: Article

References (16)

1. World Health Organization. 1995. Proposed new strategy for global TB research: a report of the Fifth Meeting of the CARG. World Health Organization/GTB/Coordination, Advisory and Review Group for the tuberculosis programme/95.5.
2. American Lung Association. 1996. The American Lung Association Conference on re-establishing control of tuberculosis in the United States. Georgetown University Conference Center, Washington DC, March 11 to 13, 1994. Am. J. Respir. Crit. Care Med. 154:251-262.
3. O'Brien, R. J. 1993. The treatment of tuberculosis. In L. B. Reichman and E. S. Hershfield, editors. Tuberculosis, A Comprehensive International Approach. Marcel Dekker, New York. 207-240.
4. World Health Organization. 1997. Treatment of tuberculosis: guidelines for national programmes, 2nd ed. World Health Organization/TB/ 97.220.
5. Ji, B., C. Truffot-Pernot, M. C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. 148:1541-1546.
6. Chapuis, L., B. Ji, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and J. H. Grosset. 1994. Preventive therapy of tuberculosis with rifapentine in immuno-competent and nude mice. Am. J. Respir. Crit. Care Med. 150:1355-1362.
7. Grosset, J., C. Truffot-Pernot, S. Poggi, H. Lecoeur, and C. Chastang. 1985. Prévention de la résistance à la rifampicine par le pyrazinamide dans la tuberculose expérimentale de la souris. Rev. Mal. Resp. 2:205-20S.
8. Godfrey, K. 1985. Statistics in practice: comparing the means of several groups. N. Engl. J. Med. 313:1450-1456.
9. David, H. L. 1970. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 20:810-814.
10. Le Lirzin, M., and V. Djurovic. 1971. Etude sur millieu de Löwenstein-Jensen de la composition des souches sauvages de Mycobacterium tuberculosis en variants résistant à la rifampicine et en variants résistant à l'éthambutol. Ann. Inst. Pasteur 120:531-548.
11. Hoescht, Marion, Roussel (HMR). 1995. Unpublished data.
12. Kenny, M. T., and B. Strates. 1981. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab. Rev. 12:159-218.
13. Singapore Tuberculosis Service/British Medical Research Council. 1977. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore: the results up to 30 months. Am. Rev. Respir. Dis. 116:807-820.
14. Cohn, D. L., B. J. Catlin, K. L. Peterson, F. N. Judson, and J. A. Sbarbaro. 1990. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann. Intern. Med. 112:407-415.
15. Grosset, J., and S. Leventis. 1983. Adverse effects of rifampin. Rev. Infect. Dis. 5(Suppl. 3):S440-S446.
16. Dickinson, S. M., and D. A. Mitchison. 1966. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 47:370-380.